Lakefront Biotherapeutics American Depositary Shares
LKFT
75 hedge funds and large institutions have $704M invested in Lakefront Biotherapeutics American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 18 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
20% more capital invested
Capital invested by funds: $585M → $704M (+$119M)
7.63% more ownership
Funds ownership: 20.01% → 27.64% (+7.6%)
0% more funds holding
Funds holding: 75 → 75 (0)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
26% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $17.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$84.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.2M |
| 3 |
Primecap Management
Pasadena,
California
|
+$27M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$24.1M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$6.22M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.69M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.68M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.66M |
| 5 |
SC
Sessa Capital
New York
|
-$2.07M |
LKFT Hedge Fund Activity: Q1 2023 in Review
75 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2023, worth a combined $704M — up 20% from $585M a quarter earlier.
Fund positioning in LKFT was balanced in Q1 2023: 18 funds opened new positions, 18 closed out, 25 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, adding an estimated $84.9M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $6.22M sold.
- 75 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $704M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2023, up 20% quarter-over-quarter.
- 18 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2023 and 18 closed out, a net change of 0 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2023 was BVF Inc, an estimated $84.9M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2023 was Ally Bridge Group, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2023.